Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis

Next Previous
Trial Profile

Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SPY 001 (Primary) ; SPY 001 (Primary) ; SPY 002 (Primary) ; SPY 002 (Primary) ; SPY 003 (Primary)
  • Indications Ulcerative colitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SKYLINE-UC
  • Sponsors Spyre Therapeutics

Most Recent Events

  • 18 Feb 2026 According to the Spyre Therapeutics Media Release, the company will share data from this study in a scientific poster presentation at the 21st Congress of the European Crohn's and Colitis Organisation (ECCO), held February 18-21, 2026 in Stockholm, Sweden.
  • 12 Jan 2026 According to the Spyre Therapeutics Media Release, enrollment in Part A has exceeded expectations with SPY001 enrollment completed ahead of schedule. Readouts for Part A are now expected to begin in Q2 2026.
  • 05 Nov 2025 According to the Spyre Therapeutics Media Release, SKYLINE and SKYWAY trials are expected to provide 6 proof-of-concept readouts in 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top